Log in

Relevant bibliographies by topics / Arousal Disorder (FSIAD) / Journal articles

To see the other types of publications on this topic, follow the link: Arousal Disorder (FSIAD).

Journal articles on the topic 'Arousal Disorder (FSIAD)'

Author: Grafiati

Published: 4 June 2025

Last updated: 1 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 30 journal articles for your research on the topic 'Arousal Disorder (FSIAD).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Gold, LauraMaery. "Three Identified and Critiqued Measures of Sexuality." Communiqué: The Relationship Institute 1, no. 3 (2018): 1–5. https://doi.org/10.5281/zenodo.4672230.

Full text

Abstract:

Abstract: Female Sexual Interest/Arousal Disorder (FSIAD), a condition described in the DSM-5, can be quantified with available psychometric tools. Three measures of FSIAD are compared. Conclusions are drawn as to their relative merits.

APA, Harvard, Vancouver, ISO, and other styles

2

Höhle, Daniël, Kim van Rooij, Jos Bloemers, et al. "A survival of the fittest strategy for the selection of genotypes by which drug responders and non-responders can be predicted in small groups." PLOS ONE 16, no. 3 (2021): e0246828. http://dx.doi.org/10.1371/journal.pone.0246828.

Full text

Abstract:

Phenotype Prediction Scores (PPS) might be powerful tools to predict traits or the efficacy of treatments based on combinations of Single-Nucleotide Polymorphism (SNPs) in large samples. We developed a novel method to produce PPS models for small samples sizes. The set of SNPs is first filtered on those known to be relevant in biological pathways involved in a clinical condition, and then further filtered repeatedly in a survival strategy to select stabile positive/negative risk alleles. This method is applied on Female Sexual Interest/Arousal Disorder (FSIAD), for which two subtypes has been

APA, Harvard, Vancouver, ISO, and other styles

3

Elanjian, Alissa I., Sesilia Kammo, Lyndsey Braman, and Aron Liaw. "Advancing Women’s Health: A Scoping Review of Pharmaceutical Therapies for Female Sexual Dysfunction." Sexes 6, no. 3 (2025): 38. https://doi.org/10.3390/sexes6030038.

Full text

Abstract:

Background: Female Sexual Dysfunction (FSD) encompasses a range of conditions that can profoundly impact quality of life and intimate relationships. The primary classifications of FSD include female sexual interest and arousal disorder (FSIAD), genitopelvic pain and penetration disorder (GPPPD), female orgasmic disorder (FOD), and substance or medication-induced sexual dysfunction (SM-ISD). Despite its prevalence, FSD is often underdiagnosed and undertreated. Objectives: This scoping review follows Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to evalua

APA, Harvard, Vancouver, ISO, and other styles

4

Balon, R. "Diagnosis and Assessment of Female sexual Dysfunction(s)." European Psychiatry 24, S1 (2009): 1. http://dx.doi.org/10.1016/s0924-9338(09)70456-0.

Full text

Abstract:

The first challenge in diagnosing female sexual dysfunction(s) originates in our diagnostic system. The traditional model of classifying sexual dysfunction is anchored in the sexual response cycle: desire - arousal - orgasm - resolution. However, as some experts have pointed out, this classification may be problematic in the area of female sexuality. Both the diagnoses of female hypoactive sexual desire disorder (FHSDD) and female arousal disorder (FSAD) probably need to be redefined and refined. Examples include adding the lack of responsive desire to the FHSDD criteria and creating categorie

APA, Harvard, Vancouver, ISO, and other styles

5

Costabile, Raymond A., James G. McMurray, Gita Singh, Mitchell Wiatrak, and Craig Peterson. "738: Topical Alprostadil for the Treatment of Premenopausal Women with Female Sexual Arousal Disorder (FSAD)." Journal of Urology 173, no. 4S (2005): 201. http://dx.doi.org/10.1016/s0022-5347(18)35970-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Basson, Rosemary, Rosemary McInnes, Mike D. Smith, and Gemma Hodgson. "Efficacy & safety of viagra® in estrogenized women with sexual dysfunction associated with female sexual arousal disorder (FSAD)." International Journal of Gynecology & Obstetrics 70 (2000): E23. http://dx.doi.org/10.1016/s0020-7292(00)82403-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Impens, Ann Julie, and James R. Seibold. "Vascular Alterations and Sexual Function in Systemic Sclerosis." International Journal of Rheumatology 2010 (2010): 1–5. http://dx.doi.org/10.1155/2010/139020.

Full text

Abstract:

Sexual dysfunction is common in systemic sclerosis (SSc). Male erectile dysfunction (MED) has been reported in around 80% of subjects and more than half of female patients fulfill criteria for diagnosis as female sexual arousal Disorder (FSAD). While some evidence supports a role for cavernosal fibrosis, abundant data suggest that MED is yet another clinical feature of SSc related to vasculopathy. The contribution of vasculopathy to the more complex issues of female sexual dysfunction is less clear. Inhibitors of Type V phosphodiesterase are effective in men with MED secondary to SSc. Limited

APA, Harvard, Vancouver, ISO, and other styles

8

Rellini, Alessandra, and Cindy Meston. "ORIGINAL RESEARCH—OUTCOMES RESEARCH: The Sensitivity of Event Logs, Self‐Administered Questionnaires and Photoplethysmography to Detect Treatment‐Induced Changes in Female Sexual Arousal Disorder (FSAD) Diagnosis." Journal of Sexual Medicine 3, no. 2 (2006): 283–91. http://dx.doi.org/10.1111/j.1743-6109.2005.00153.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

PADMA-NATHAN, HARIN, CANDACE BROWN, JANE FENDL, SHAWKI SALEM, JAMES YEAGER, and RONALD HARNINGR. "Efficacy and Safety of Topical Alprostadil Cream for the Treatment of Female Sexual Arousal Disorder (FSAD): A Double-Blind, Multicenter, Randomized, and Placebo-Controlled Clinical Trial." Journal of Sex & Marital Therapy 29, no. 5 (2003): 329–44. http://dx.doi.org/10.1080/00926230390224710.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Lao, Q. P., M. Zhang, J. S. Bai, M. Y. Huang, J. Mo, and M. Lu. "Enhanced Effects of Specially Formulated Topical Alprostadil Cream by a Continuous Dosing Remedy for the Treatment of Female Sexual Arousal Disorder (FSAD) in a Double-Blind, Multicenter, Randomized, and Placebo-Controlled Clinical Trial." Fertility and Sterility 84 (September 2005): S131—S132. http://dx.doi.org/10.1016/j.fertnstert.2005.07.321.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Orri, Miguel, Lucy Abraham, and Annamaria Giraldi. "A Phase 2a Multicenter, Double‐Blind, Placebo‐Controlled, Crossover Trial to Investigate the Efficacy, Safety, and Toleration of CP‐866,087 (a High‐Affinity Mu‐Opioid Receptor Antagonist) in Premenopausal Women Diagnosed with Female Sexual Arousal Disorder (FSAD)." Journal of Sexual Medicine 10, no. 10 (2013): 2484–96. http://dx.doi.org/10.1111/jsm.12071.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Shindel, A. W. "A Phase 2a Multicenter, Double-Blind, Placebo-Controlled, Crossover Trial to Investigate the Efficacy, Safety, and Toleration of CP-866,087 (a High-Affinity Mu-Opioid Receptor Antagonist) in Premenopausal Women Diagnosed with Female Sexual Arousal Disorder (FSAD)." Yearbook of Urology 2014 (2014): 106–7. http://dx.doi.org/10.1016/j.yuro.2014.01.017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Torres, Dr Laura R., Sònia A. Acedo, and Prof Camil C.-B. Flores. "(266) BRAIN ACTIVATION PATTERNS IN POSTMENOPAUSAL WOMEN WITH SEXUAL DESIRE-AROUSAL DISORDER: PRELIMINARY RESULTS." Journal of Sexual Medicine 21, Supplement_4 (2024). http://dx.doi.org/10.1093/jsxmed/qdae041.065.

Full text

Abstract:

Abstract Objectives To define brain activation patterns in postmenopausal women with FSIAD during visual and olfactory sexual stimulation. Methods A cross-sectional study in a tertiary university hospital is being conducted with postmenopausal women with FSIAD (N=18) and postmenopausal women without FSIAD (N=5). A functional magnetic resonance imaging (fMRI) has been performed to measure brain blood flow and oxygen level dependent changes induced by neuronal activation during visual and olfactory stimuli (non-sexual, neutral, sexual). Results The mean age (mean ± SD) of our sample is 55,8 ± 6,

APA, Harvard, Vancouver, ISO, and other styles

14

Weiss, Judith, Regina Steil, Kathlen Priebe, et al. "Sexual Dysfunctions in Women with Posttraumatic Stress Disorder Following Childhood Sexual Abuse: Prevalence Rates According to DSM-5 and Clinical Correlates." Archives of Sexual Behavior, July 19, 2023. http://dx.doi.org/10.1007/s10508-023-02652-0.

Full text

Abstract:

AbstractMany women with posttraumatic stress disorder (PTSD) after child sexual abuse (CSA) suffer from sexual problems. However, little is known about the frequency of female sexual dysfunctions (FSD) as defined by DSM-5 among women with PTSD due to CSA. Furthermore, factors related to FSD in this patient population are understudied. To assess prevalence rates and clinical correlates of FSD according to DSM-5 criteria in women with PTSD after CSA, a structured clinical interview for sexual dysfunctions according to DSM-5 criteria was administered in a sample of 137 women with PTSD after CSA.

APA, Harvard, Vancouver, ISO, and other styles

15

Wix, Richard Joseph, and Ezequiel Uribe. "Benzodiazepines, Amphetamines, Testosterone and Sildenafil as New Candidates Drugs for Sexual Interest, Desire and/or Arousal Disorder." Current Psychopharmacology 10 (March 1, 2021). http://dx.doi.org/10.2174/2211556010666210301144022.

Full text

Abstract:

Background: The FDA approved drugs for female sexual interest, desidere and/or arousal disorder (FSIAD), and hypoactive sexual desire disorder (HSDD), however this have low tolerability for patients because its multiple side effects and does not show real therapeutic efficacy. Hypoactive Sexaul Desire affects from 750.000.000 to 1.400.000.000 people worldwide. Methods: In this paper we analyze therapeutic candidate in clinical practice as well as the methodologies clinical trials of possible therapeutic targets of different systems related to the dysfunction. Results: Therefore New Drugs (Benz

APA, Harvard, Vancouver, ISO, and other styles

16

Farahi, Zahra, Mozhgan HashemZadeh, and Farnaz Farnam. "Sexual counseling for female sexual interest/arousal disorders: a randomized controlled trial based on the “good enough sex” model." Journal of Sexual Medicine, January 4, 2024. http://dx.doi.org/10.1093/jsxmed/qdad168.

Full text

Abstract:

Abstract Background Female sexual interest/arousal disorder (FSIAD) is the most common female sexual disorder with adverse effects on women’s health and interpersonal relationships. Aim This survey evaluated the effects of sexual counseling based on the “good enough sex” (GES) model on the sexual health variables of women with FSIAD. Methods A randomized clinical trial with a 1:1 allocation ratio was conducted among 80 women with FSIAD in Iran in 2021. Eligible participants were randomly assigned to group A (women) and group B (couples). Women attended 4 weekly online group sexual counseling s

APA, Harvard, Vancouver, ISO, and other styles

17

Reisman, Y., L. Vignozzi, R. Nappi, et al. "(215) Design of the ALETTA Clinical Study: A Randomized Double-Blind Placebo-Controlled Study investigating the Efficacy and Safety of LybridoTM in Premenopausal Women with Acquired FSIAD." Journal of Sexual Medicine 20, Supplement_1 (2023). http://dx.doi.org/10.1093/jsxmed/qdad060.206.

Full text

Abstract:

Abstract Introduction Low sexual desire is the most common sexual complaint in women. As a result, many women suffer from sexual dissatisfaction and related distress which often negatively interferes with their quality of life. Currently, limited drug treatments are available globally to treat women with Hypoactive Sexual Desire Disorder/Female Sexual Interest & Arousal Disorder (FSIAD). Consequently, there is an unmet need, and relevance to developing a drug treatment for women with sexual dysfunction. LybridoTM is a novel on-demand dual-route/dual release fixed-dose combination tablet of

APA, Harvard, Vancouver, ISO, and other styles

18

Prof. Yacov, Reisman, Vignozzi Prof. Linda, Nappi Prof. Rossella, et al. "(160) THE ALETTA CLINICAL STUDY: DESIGN OF A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY INVESTIGATING THE EFFICACY AND SAFETY OF LYBRIDOTM IN PREMENOPAUSAL WOMEN WITH ACQUIRED FSIAD." Journal of Sexual Medicine 20, Supplement_4 (2023). http://dx.doi.org/10.1093/jsxmed/qdad062.165.

Full text

Abstract:

Abstract Objectives Low sexual desire is the most common sexual complaint in women. As a result, many women suffer from sexual dissatisfaction and related distress which often negatively interferes with their quality of life. Currently, limited drug treatments are available globally to treat women with Female Sexual Interest & Arousal Disorder (FSIAD). As a result, there is an unmet need, and relevance to develop a drug treatment for women with sexual dysfunction. LybridoTM (Freya Pharma Solutions, Amsterdam, the Netherlands) is a novel on-demand dual route/dual release fixed dose combinat

APA, Harvard, Vancouver, ISO, and other styles

19

Wente, K., and S. Dugan. "(093) HOW FREQUENTLY AND IN WHAT DOMAINS ARE HEALTHCARE PROVIDERS ASSESSING SEXUAL FUNCTION IN MIDLIFE FEMALES WITH URINARY INCONTINENCE? A DIRECTED CONTENT ANALYSIS APPROACH." Journal of Sexual Medicine 22, Supplement_1 (2025). https://doi.org/10.1093/jsxmed/qdaf068.083.

Full text

Abstract:

Abstract Introduction Female sexual dysfunction (FSD) affects nearly half of all midlife women, contributing to reduced quality-of-life and may be an early predictor of other chronic health conditions. FSD is especially common in midlife women with pelvic floor dysfunction, such as urinary incontinence (UI). There is little research that investigates how healthcare providers are assessing sexual function in female patients presenting with complaints of urinary incontinence. Objective To investigate the types and depth of sexual function assessment performed by healthcare providers evaluating e

APA, Harvard, Vancouver, ISO, and other styles

20

Symonds, Tara, Sheryl A. Kingsberg, James A. Simon, et al. "Symptoms and associated impact in pre- and postmenopausal women with sexual arousal disorder: a concept elicitation study." Journal of Sexual Medicine, January 23, 2023. http://dx.doi.org/10.1093/jsxmed/qdac043.

Full text

Abstract:

Abstract Background Approximately 26% of adult women in the United States suffer from female sexual arousal disorder (FSAD), yet little has been done to compare the experience of FSAD in pre- and postmenopausal women, which is critical to enhance the current understanding of FSAD and inform the development and assessment of treatment options for these patient populations. Aim To explore the experience of condition-associated symptoms and the relative importance of FSAD symptoms, including their severity, bother, and impact, on participants’ health-related quality of life (HRQoL) in pre- and po

APA, Harvard, Vancouver, ISO, and other styles

21

Thurman, A., K. Cornell, T. Symonds, et al. "(093) IMPACT OF ENROLLMENT DIAGNOSIS ON EFFICACY ENDPOINTS IN AN EXPLORATORY, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF SILDENAFIL CREAM, 3.6% FOR THE TREATMENT OF FEMALE SEXUAL AROUSAL DISORDER." Journal of Sexual Medicine 21, Supplement_5 (2024). http://dx.doi.org/10.1093/jsxmed/qdae054.088.

Full text

Abstract:

Abstract Introduction There are no FDA-approved treatments for female sexual arousal disorder (FSAD). Women with FSAD also often have co-existing secondary female sexual dysfunction (FSD) diagnoses. Objective Post-hoc subset analysis of the effect of enrollment FSD diagnoses on efficacy of Sildenafil Cream, 3.6% for treatment of FSAD. Methods Phase 2b, exploratory, randomized, placebo-controlled, double-blind study of Sildenafil Cream, 3.6% among premenopausal women with FSAD (NCT04948151). The change from baseline at week 12 in the arousal sensation (AS) domain (questions 6-9) of the 28-quest

APA, Harvard, Vancouver, ISO, and other styles

22

Thurman, A., K. Cornell, T. Symonds, et al. "(094) MEASURES OF FEMALE SEXUAL DISTRESS IN AN EXPLORATORY, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF SILDENAFIL CREAM, 3.6% FOR THE TREATMENT OF FEMALE SEXUAL AROUSAL DISORDER." Journal of Sexual Medicine 21, Supplement_5 (2024). http://dx.doi.org/10.1093/jsxmed/qdae054.089.

Full text

Abstract:

Abstract Introduction The diagnosis of female sexual arousal disorder (FSAD) requires that individuals experience clinically significant distress from their symptoms. Pre-trial content validity investigations were conducted by the sponsor to understand how women with FSAD best described their distress associated with this female sexual dysfunction (FSD) diagnosis. Objective Responses to the Female Sexual Distress Scale – Desire, Arousal, Orgasm (FSDS-DAO) survey among healthy premenopausal women enrolled in a Phase 2b, exploratory, randomized, placebo-controlled, double-blind study of Sildenaf

APA, Harvard, Vancouver, ISO, and other styles

23

Dr. Jesús E, Rodríguez, Martínez Lucrecia, and Bonachera Natalia. "(94) A COGNITIVE BEHAVIORAL INTERVENTION FOR FEMALE SEXUAL AROUSAL DISORDERS USING A VIBRATING DEVICE." Journal of Sexual Medicine 20, Supplement_4 (2023). http://dx.doi.org/10.1093/jsxmed/qdad062.038.

Full text

Abstract:

Abstract Objectives We will investigate the safety and preliminary evidence of the effectiveness of a new Cognitive Behavioral Therapy (CBT) in combination with a vibrating device for the treatment of Female Sexual Arousal Disorders (FSAD). Methods A one-group pretest-posttest multicenter design was used. Main outcome measure was assessed using the Female Sexual Function Index (FSFI). A total of 16 patients aged between 19 and 48 years of age (mean = 28.12 years, standard deviation (SD) = 1.92) met criteria and were instructed in the use of a small, portable vibration device over 12 weeks. The

APA, Harvard, Vancouver, ISO, and other styles

24

Thurman, A., J. Simon, SA Kingsberg, et al. "(123) Preliminary Efficacy of Sildenafil Cream, 3.6% in an Exploratory, Randomized, Placebo-Controlled, Phase 2b Trial for the Treatment of Female Sexual Arousal Disorder." Journal of Sexual Medicine 21, Supplement_1 (2024). http://dx.doi.org/10.1093/jsxmed/qdae001.117.

Full text

Abstract:

Abstract Introduction Female sexual arousal disorder (FSAD) is a persistent or recurrent inability to attain, or to maintain until completion of the sexual activity, an adequate lubrication-swelling response of sexual excitement that causes marked distress or interpersonal difficulty. The biologic mechanisms leading to FSAD are similar to male erectile dysfunction. Objective To test the preliminary efficacy of topical Sildenafil Cream, 3.6% among women with FSAD in a randomized, placebo-controlled, double-blind, exploratory Phase 2b study. To describe, using validated 28-day recall instruments

APA, Harvard, Vancouver, ISO, and other styles

25

Haider, Rehan. "Sexual Dysfunction." Women's Health Science Journal 8, no. 1 (2024). http://dx.doi.org/10.23880/whsj-16000209.

Full text

Abstract:

Sexual disorder refers to a wide variety of problems that may affect a man’s or woman’s ability to enjoy intercourse and make healthy sexual connections. It consists of miscellaneous problems that have connections with lust, arousal, appearance, and vindication and can deeply impact an individual’s standard satisfaction of boom and intellectual fitness. There are various normal forms of sexual disorder. Erectile dysfunction (ED), as an example, is the failure to acquire or uphold enough erection to make love, typically shifting partners. On the other hand, wives can also enjoy environments suc

APA, Harvard, Vancouver, ISO, and other styles

26

Rodriguez, JE, R. Dadian, V. Suarez, and MDM Martinez. "(051) SUCCESSFUL TREATMENT OF FEMALE SEXUAL AROUSAL DISORDER USING A PATTERN OF FOCUSED MECHANICAL VIBRATION VIA A PORTABLE VIBRATING DEVICE." Journal of Sexual Medicine 21, Supplement_6 (2024). https://doi.org/10.1093/jsxmed/qdae161.040.

Full text

Abstract:

Abstract Introduction Vaginal dryness is one of the most common gynecological concerns related to sexual activity. Vaginal dryness can occur for many reasons, not always physiological or pathological. Lubrication is an expression of sexual arousal, so dryness can also occur due to lack of arousal, either because more stimulation is needed or because the conditions are not suitable. In many cases, this dryness can cause discomfort and/or pain during sexual intercourse. Ultimately, this can lead to decreased interest in sexual relations over the medium and long term. Portable vibrators are commo

APA, Harvard, Vancouver, ISO, and other styles

27

Johnson, Isabella, Andrea Ries Thurman, Katherine A. Cornell, et al. "Impact of age, race, and medication use on efficacy endpoints in a randomized controlled trial of topical sildenafil cream for the treatment of female sexual arousal disorder." Sexual Medicine 12, no. 5 (2024). http://dx.doi.org/10.1093/sexmed/qfae079.

Full text

Abstract:

Abstract Background A study of topical Sildenafil Cream 3.6% was completed among healthy premenopausal women with female sexual arousal disorder. Aims To compare efficacy endpoints based on product use in pre-planned and post-hoc subsets of age, race, and medication use. Methods Phase 2b, exploratory, randomized, placebo-controlled, double-blind study of Sildenafil Cream, 3.6% among healthy premenopausal women with female sexual arousal disorder (FSAD). Eligible participants were randomized 1:1 to Sildenafil versus Placebo Cream and used investigational product for 12 weeks. Outcomes The co-pr

APA, Harvard, Vancouver, ISO, and other styles

28

Thurman, A., K. Cornell, T. Symonds, et al. "(092) SEXUAL EXPERIENCES IN AN EXPLORATORY, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF SILDENAFIL, 3.6% CREAM FOR THE TREATMENT OF FEMALE SEXUAL AROUSAL DISORDER." Journal of Sexual Medicine 21, Supplement_5 (2024). http://dx.doi.org/10.1093/jsxmed/qdae054.087.

Full text

Abstract:

Abstract Introduction Quantifying the change in the mean number of satisfactory sexual experiences (SSEs) is an efficacy endpoint recommended by the US Food and Drug Administration in studies of treatments for female sexual dysfunctions (FSD), including female sexual arousal disorder (FSAD). Objective Post-hoc analysis of sexual experiences in a study of Sildenafil Cream, 3.6% for treatment of FSAD Methods Phase 2b, exploratory, randomized, placebo-controlled, double-blind study of Sildenafil Cream, 3.6% among premenopausal women with FSAD (NCT04948151). Following a baseline, single-blind, pla

APA, Harvard, Vancouver, ISO, and other styles

29

Goldstein, Irwin, Bassam Damer, Daniel Frank, Mohamed Hachica, Ysabella Fernanco, and Joachim Schupp. "1498 UPDATED ANALYSES OF A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF FEMPROX®, AN ALPROSTADIL CREAM WITH A NOVEL TRANSDERMAL DELIVERY TECHNOLOGY FOR THE TREATMENT OF FEMALE SEXUAL AROUSAL DISORDER (FSAD)." Journal of Urology 187, no. 4S (2012). http://dx.doi.org/10.1016/j.juro.2012.02.2020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Pyke, R. "(497) Is Drug Development for Female Sexual Dysfunction Dead?" Journal of Sexual Medicine 20, Supplement_1 (2023). http://dx.doi.org/10.1093/jsxmed/qdad060.469.

Full text

Abstract:

Abstract Introduction Various agents have been tested to treat female sexual dysfunction (FSD), particularly Hypoactive Sexual Desire Disorder and Female Sexual Arousal Disorder, but only two, flibanserin and bremelanotide, have met any regulatory standards (US only), and none is popular with patients or prescribers. Several more agents, e.g., sildenafil, testosterone, alprostadil, buspirone, bupropion and trazodone, have shown early promise but have not been developed further. Objective Evaluate whether drug development for FSD at a standstill and identify related factors. Methods Selective l

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!